Accelerating Drug Development
with​
Model-Informed & Data Science

We are a quantitative pharmacology and data science team focused on helping biotech companies make better, faster, and more confident drug development decisions.
​
​Our expertise spans pharmacometrics, model-based meta-analysis, machine learning, and real-world evidence. By integrating these capabilities, we deliver a unified, model-informed approach that supports development strategy from early clinical stages through to commercialization.

Our Services

Quantitative Pharmacology & Model-Informed Drug Development​​

​Model-Based Meta-Analysis ​(MBMA&NMA)

AI-Enhanced Modeling &
​Machine Learning​

Real-World Evidence &
​Advance Data Science

Therapeutic Areas

We focus on high-impact and complex therapeutic areas where quantitative pharmacology and model-informed approaches can provide the greatest value. These include oncology, antibody-drug conjugates (ADCs), oligonucleotides, immunology, rare diseases, and special populations.

Our expertise is particularly valuable in settings characterized by high variability, limited data, complex mechanisms, or challenging clinical endpoints—where integrated modeling and data-driven approaches can significantly improve decision-making.